leadf
logo-loader
viewMedlab Clinical Ltd

Medlab Clinical completes first order of new hybrid cannabinoid to UK

The combination of two formulations, Mg Optima Relax and CBD, promote relaxation and reduces stress.

Medlab Clinical Ltd - Medlab Clinical completes first order of new cannabinoid to UK
The first order of 5,000 units has been manufactured for Cultech Ltd.

Medlab Clinical Ltd (ASX:MDC) has completed the first order of its newly developed hybrid cannabinoid, Mg Optima Relax + CBD, which has been manufactured for Cultech Ltd in the UK.

In line with an exclusive UK/US distribution agreement of December 2019 to expand into the UK, the product has been manufactured and will be exported under licence to the UK.

The first order of 5,000 units is awaiting an 'ex-works' collection

Part of the agreement was the supply of a cannabinoid product combining Mg Optima Relax, a current Medlab nutraceuticals formulation available in Australian pharmacies and CBD that is used in the NanoCBD™ manufacture.

The product was developed in the USA and manufactured by American Nutritional Corp Inc.

After several months of development, the product has been manufactured in accordance to Cultech’s requirements for 5,000 units.

“First meaningful export for agreement”

Chief executive officer Sean Hall said: “This is our first meaningful export for this trade agreement and I see this as a start of great potential as we develop UK markets.”

Magnesium (Mg) has well-known benefits for stress reduction, sleep, and mitigating restless legs.

Mg Optima Relax as a nutraceutical (that being with no CBD) is well placed in the Australian marketplace as a Medlab nutraceutical.

The combination of the two formulations (Mg Optima Relax and CBD) adds to the overall story of promoting relaxation and reducing stress.

Hall continued: “This product is not for Australia because of our laws relating to CBD use, but primed for other global legal markets.

“We would envisage a more global play regarding this product, as most Westerners are well versed in the benefits of magnesium, and hence its relatively easy to understand the synergistic benefits of combining magnesium and CBD.”

Shares are up 7% to 15 cents.

Quick facts: Medlab Clinical Ltd

Price: 0.205 AUD

ASX:MDC
Market: ASX
Market Cap: $57.33 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Medlab Clinical Ltd named herein, including the promotion by the Company of Medlab Clinical Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Medlab Clinical forges ahead in new vitamin trials for chronic illnesses

Medlab Clinical Ltd (ASX:MDC) chief executive officer Sean Hall tells Proactive Investors how the company is tapping into new areas of its “therapeutic toolkit” to better assist those with chronic health conditions.   Hall says there has been a shortfall in the standard of...

on 05/07/2019

2 min read